Inozyme Pharma, Inc.

General ticker "INZY" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $222.1M (TTM average)

Inozyme Pharma, Inc. does not follow the US Stock Market performance with the rate: -3.6%.

Estimated limits based on current volatility of 5.0%: low 0.96$, high 1.06$

Factors to consider:

  • Earnings expected soon, date: 2025-05-06 bmo
  • Current price 36.9% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [1.55$, 5.02$]
  • 2025-12-31 to 2026-12-31 estimated range: [1.37$, 4.35$]

Financial Metrics affecting the INZY estimates:

  • Negative: Non-GAAP EPS, $ of -1.63 <= 0.04
  • Negative: Operating cash flow per share per price, % of -34.09 <= 1.79
  • Negative: negative Operating income
  • Positive: 43.26 < Shareholder equity ratio, % of 46.94 <= 63.75
  • Positive: Interest expense per share, $ of 0.09 <= 0.10
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82

Similar symbols

Short-term INZY quotes

2025-03-122025-03-132025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-230.750.80.850.90.9511.051.1
Price $

Long-term INZY plot with estimates

123456789Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.4−0.3−0.2−0.10
INZYS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $68.67MM $75.64MM $104.03MM
Operating Income $-68.67MM $-75.64MM $-104.03MM
Non-Operating Income $1.61MM $4.48MM $2.01MM
Interest Expense $0.26MM $3.33MM $5.56MM
R&D Expense $47.85MM $54.85MM $83.23MM
Income(Loss) $-67.06MM $-71.17MM $-102.02MM
Profit(Loss)* $-65.45MM $-71.17MM $-102.02MM
Stockholders Equity $118.39MM $140.48MM $57.83MM
Inventory $0.12MM $0.00MM $0.00MM
Assets $139.19MM $200.85MM $123.18MM
Operating Cash Flow $-57.76MM $-70.67MM $-91.91MM
Capital expenditure $0.41MM $0.30MM $0.06MM
Investing Cash Flow $-5.40MM $-53.65MM $67.00MM
Financing Cash Flow $72.79MM $125.97MM $11.40MM
Earnings Per Share** $-1.73 $-1.37 $-1.62

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.